Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel
Sponsor: Sironax USA, Inc.
Summary
This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).
Official title: A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2026-08-21
Completion Date
2027-12-31
Last Updated
2026-10-01
Healthy Volunteers
No
Interventions
SIR2501
Experimental: 30 mg SIR2501 administered at 30 mg dose level. Experimental: 45 mg SIR2501 administered at 45 mg dose level. Experimental: 60 mg SIR2501 administered at 60 mg dose level.
Locations (3)
Hollywood, Florida, United States
Baltimore, Maryland, United States
East Brunswick, New Jersey, United States